Immunitybio Total Assets from 2010 to 2025

IBRX Stock

USD 2.71 0.04 1.45%

Immunitybio Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 299.1 M in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2014-12-31

Previous Quarter

364.6 M

Current Value

382.9 M

Quarterly Volatility

109 M

Yuan Drop

Covid

Check Immunitybio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunitybio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.5 M, Interest Expense of 138.2 M or Selling General Administrative of 100.2 M, as well as many indicators such as Price To Sales Ratio of 115, Dividend Yield of 0.0 or Days Sales Outstanding of 55.5. Immunitybio financial statements analysis is a perfect complement when working with Immunitybio Valuation or Volatility modules.

Check out the analysis of Immunitybio Correlation against competitors.

For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.

Latest Immunitybio's Total Assets Growth Pattern

Below is the plot of the Total Assets of Immunitybio over the last few years. Total assets refers to the total amount of Immunitybio assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Immunitybio books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Immunitybio's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunitybio's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 382.93 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Immunitybio Total Assets Regression Statistics

	Arithmetic Mean	223,013,870
	Geometric Mean	78,220,890
	Coefficient Of Variation	77.70
	Mean Deviation	146,052,120
	Median	250,440,000
	Standard Deviation	173,282,107
	Sample Variance	30026.7T
	Range	502.3M
	R-Value	0.80
	Mean Square Error	11765T
	R-Squared	0.63
	Significance	0.0002
	Slope	28,987,301
	Total Sum of Squares	450400.3T

Immunitybio Total Assets History

	2025	299.1 M
	2024	382.9 M
	2023	504.5 M
	2022	362.4 M
	2021	468.9 M
	2020	221.4 M
	2019	143.1 M

Other Fundumenentals of Immunitybio

Intangibles To Total Assets

Immunitybio Total Assets component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Short Term Investments	Capital Surpluse	Property Plant Equipment	Net Tangible Assets	Long Term Debt	Net Invested Capital	Long Term Investments	Capital Stock	Net Working Capital	Deferred Long Term Liab	Short Long Term Debt
Total Assets		-0.44	-0.83	0.48	-0.74	0.63	0.23	0.74	0.95	0.42	0.61	0.67	-0.37	0.72	0.67	-0.68	0.57	0.09	-0.72	0.51	0.0	-0.22	0.56
Total Stockholder Equity	-0.44		0.32	-0.56	0.87	-0.63	0.02	-0.92	-0.27	-0.41	-0.67	-0.86	0.73	-0.86	-0.85	0.92	-0.72	0.2	0.89	-0.74	-0.01	0.5	-0.83
Current Deferred Revenue	-0.83	0.32		-0.34	0.7	-0.59	-0.44	-0.59	-0.69	-0.3	-0.59	-0.62	0.54	-0.6	-0.59	0.6	-0.37	0.04	0.54	-0.39	0.04	0.3	-0.45
Net Debt	0.48	-0.56	-0.34		-0.44	0.83	0.0	0.58	0.35	0.78	0.32	0.29	-0.29	0.64	0.37	-0.58	0.25	0.59	-0.52	0.03	-0.49	0.29	0.29
Retained Earnings	-0.74	0.87	0.7	-0.44		-0.68	-0.16	-0.97	-0.57	-0.36	-0.79	-0.98	0.76	-0.91	-0.93	0.96	-0.73	0.28	0.92	-0.81	-0.07	0.63	-0.86
Accounts Payable	0.63	-0.63	-0.59	0.83	-0.68		0.05	0.72	0.45	0.81	0.55	0.56	-0.49	0.78	0.64	-0.77	0.21	0.3	-0.68	0.23	-0.58	-0.09	0.53
Net Receivables	0.23	0.02	-0.44	0.0	-0.16	0.05		0.09	0.16	-0.05	0.01	0.11	-0.25	0.06	0.09	-0.06	0.12	-0.1	-0.05	0.09	0.08	-0.06	0.08
Total Liab	0.74	-0.92	-0.59	0.58	-0.97	0.72	0.09		0.59	0.46	0.76	0.94	-0.7	0.92	0.93	-0.97	0.77	-0.15	-0.96	0.76	0.03	-0.53	0.85
Total Current Assets	0.95	-0.27	-0.69	0.35	-0.57	0.45	0.16	0.59		0.32	0.42	0.53	-0.13	0.54	0.49	-0.49	0.5	0.17	-0.59	0.38	0.1	-0.16	0.35
Short Term Debt	0.42	-0.41	-0.3	0.78	-0.36	0.81	-0.05	0.46	0.32		0.33	0.22	-0.19	0.53	0.39	-0.48	-0.11	0.64	-0.55	-0.06	-0.82	0.1	0.28
Intangible Assets	0.61	-0.67	-0.59	0.32	-0.79	0.55	0.01	0.76	0.42	0.33		0.75	-0.78	0.67	0.83	-0.84	0.6	-0.37	-0.75	0.68	-0.1	-0.51	0.86
Common Stock	0.67	-0.86	-0.62	0.29	-0.98	0.56	0.11	0.94	0.53	0.22	0.75		-0.73	0.85	0.92	-0.92	0.75	-0.41	-0.89	0.85	0.2	-0.74	0.85
Short Term Investments	-0.37	0.73	0.54	-0.29	0.76	-0.49	-0.25	-0.7	-0.13	-0.19	-0.78	-0.73		-0.66	-0.75	0.79	-0.57	0.43	0.63	-0.64	-0.01	0.48	-0.77
Capital Surpluse	0.72	-0.86	-0.6	0.64	-0.91	0.78	0.06	0.92	0.54	0.53	0.67	0.85	-0.66		0.82	-0.93	0.63	-0.03	-0.88	0.72	-0.11	-0.32	0.82
Property Plant Equipment	0.67	-0.85	-0.59	0.37	-0.93	0.64	0.09	0.93	0.49	0.39	0.83	0.92	-0.75	0.82		-0.92	0.7	-0.33	-0.93	0.8	0.0	-0.67	0.9
Net Tangible Assets	-0.68	0.92	0.6	-0.58	0.96	-0.77	-0.06	-0.97	-0.49	-0.48	-0.84	-0.92	0.79	-0.93	-0.92		-0.71	0.21	0.92	-0.75	0.08	0.5	-0.89
Long Term Debt	0.57	-0.72	-0.37	0.25	-0.73	0.21	0.12	0.77	0.5	-0.11	0.6	0.75	-0.57	0.63	0.7	-0.71		-0.42	-0.68	0.83	0.57	-0.41	0.71
Net Invested Capital	0.09	0.2	0.04	0.59	0.28	0.3	-0.1	-0.15	0.17	0.64	-0.37	-0.41	0.43	-0.03	-0.33	0.21	-0.42		0.08	-0.62	-0.58	0.67	-0.47
Long Term Investments	-0.72	0.89	0.54	-0.52	0.92	-0.68	-0.05	-0.96	-0.59	-0.55	-0.75	-0.89	0.63	-0.88	-0.93	0.92	-0.68	0.08		-0.74	0.07	0.56	-0.83
Capital Stock	0.51	-0.74	-0.39	0.03	-0.81	0.23	0.09	0.76	0.38	-0.06	0.68	0.85	-0.64	0.72	0.8	-0.75	0.83	-0.62	-0.74		0.42	-0.63	0.9
Net Working Capital	0.0	-0.01	0.04	-0.49	-0.07	-0.58	0.08	0.03	0.1	-0.82	-0.1	0.2	-0.01	-0.11	0.0	0.08	0.57	-0.58	0.07	0.42		-0.29	0.02
Deferred Long Term Liab	-0.22	0.5	0.3	0.29	0.63	-0.09	-0.06	-0.53	-0.16	0.1	-0.51	-0.74	0.48	-0.32	-0.67	0.5	-0.41	0.67	0.56	-0.63	-0.29		-0.55
Short Long Term Debt	0.56	-0.83	-0.45	0.29	-0.86	0.53	0.08	0.85	0.35	0.28	0.86	0.85	-0.77	0.82	0.9	-0.89	0.71	-0.47	-0.83	0.9	0.02	-0.55

Click cells to compare fundamentals

About Immunitybio Financial Statements

Immunitybio investors use historical fundamental indicators, such as Immunitybio's Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunitybio. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	382.9 M	299.1 M
Intangibles To Total Assets	0.04	0.07

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC